Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
Actinogen Medical
Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program
May 28, 2026
Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
April 1, 2026
Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial
February 2, 2026